MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Ref. No.: MEDIORG/SE/2026-27/34

Saturday, November 14, 2026

To,
The Manager-Listing,
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400051, India

NSE Symbol: MEDIORG
Company ISIN: INE0PE401018

Subject: **Statement on Deviation(s) or Variation(s) of funds pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half-year ended on September 30, 2026.**

Reference: **Outcome of the meeting of the Board of Directors of Medicamen Organics Limited held on Saturday, November 14, 2026.**

Dear Sir/Madam,

In compliance with Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), along with the relevant provisions of SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, read with NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 ("**SEBI Circulars**"), and other applicable master circulars, circulars, guidelines, regulations and notifications, as issued by the Securities and Exchange Board of India ("**SEBI**"), we, Medicamen Organics Limited ("**Company**"), would like to submit a Statement on Deviation(s) or Variation(s) for proceeds preferential allotment of equity shares and warrants.of the Company for the half-year ended September 30, 2026, enclosed as **Annexure - A**.

The Certificate issued by the Statutory Auditors in respect of utilisation of issue proceeds in terms of NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, is also enclosed as **Annexure – B.**

The aforesaid statement/certificate has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on today i.e. Saturday, November 30, 2026.

The above-stated Statement on Deviation(s) or Variation(s) is also being submitted in XBRL mode along with the unaudited financial results of the Company for the half-year ended September 30, 2026.

The disclosure will also be uploaded on the website of the Company at https://www.medicamenorganics.com/.

MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Kindly take the above information on record and oblige.

Thanking You
For **Medicamen Organics Limited**

MEDICAMEN ORGANICS LTD. DELHI

Divya Sharma
Company Secretary & Compliance Officer
Membership No.: A43980
Place: New Delhi

Enclosed: As above

MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

STATEMENT ON DEVIATION / VARIATION IN UTILISATION OF FUNDS RAISED

Name of listed entity	Medicamen Organics Limited
Mode of Fund Raising	Preferential Issue via allotment of equity share and convertible warrants
Date of Raising Funds	June 9, 2026
Amount Raised	INR 13,65,00,000 An amount of INR 12,28,74,981 was raised upon preferential allotment of equity shares and warrants. Remaining consideration payable against the outstanding warrants i.e. INR 1,36,25,019 as of September 30, 2026 is yet to be received as per the issue terms.
Report filed for Half-Year ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil

MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (INR)	Modified allocation , if any	Funds Utilised (INR)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Working capital requirements	Not Applicable	10,16,60,516	Not Applicable	8,80,28,743	Not Applicable	
General corporate purposes	Not Applicable	2,12,14,465	Not Applicable	2,12,14,465	Not Applicable	
Total		**12,28,74,981**		**10,92,43,208**	Not Applicable	

Part of the Issue proceeds intended to be used for the specified objects, as per extra-ordinary general meeting held on April 9, 2026 is pending for utilization and is lying in Company's designated bank account(s), as on September 30th, 2026

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

Signature	
Name of Signatory	Bal Kishan Gupta
Designation	Chairman & Managing Director
Date	November 14, 2026

For **Medicamen Organics Limited**



Bal Kishan Gupta
Chairman and Managing Director
DIN: 00032772

N C RAJ & ASSOCIATES

Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +911149057181
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 021949

To,
National Stock Exchange Limited
Exchange Plaza, C-1 Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051.

NSE Symbol: MEDIORG

Subject: Certificate on Utilization of Funds Raised through Issue Proceeds.

We, N C Raj & Associates, FRN: 002249N, Statutory Auditor of **M/s MEDICAMEN ORGANICS LIMITED**, hereby certify that the Company raised funds from the following sources, and the details of the original allocation and actual utilization of funds are as follows:

1. **Preferential Issue including Convertible Share Warrant and Conversion of unsecured loan into shares:** The original allocation of funds in relation to the proceeds and the actual utilization of funds towards the objects of the issue for the Half year ended September 30, 2026, are detailed in Annexure A.

We further certify that the above certificate has been issued by us on the specific request of the concern on the basis of the information/ documents provided to us.

For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN: 002249N)

SANJAY GARG
Digitally signed by SANJAY GARG
Date: 2026.11.14 21:13:08 +05'30'

(SANJAY GARG)
Partner
Mem. No. 088636
Date: 14/11/2026
Place: New Delhi
UDIN: 26088636UVMVIY1139

Encl.: Annexure A

Annexure A in accordance with NSE Circular No. NSE/CML/2024/23 dated September 05, 2024

Objects for which funds have been raised and where there has been utilised in the following table:

UTILIZATION OF FUND

(Rs. in INR)

Object as Disclosed in the Offer Document	Amount disclosed in the Document	Actual Utilised Amount (As on 30th September, 2026)	Balance available	Revised Object #	Utilisation Planned as per prospectus and revised object	Amount Pending for Utilisation
Working Capital Requirement	10,16,60,516	8,80,28,743	1,36,31,773	-	-	-
General corporate purpose	2,12,14,465	2,12,14,465	-	-	-	-
Total	**12,28,74,981**	**10,92,43,208**	**1,36,31,773**	**-**	**-**	**-**

Part of the Issue proceeds intended to be used for the specified objects, as per extra-ordinary general meeting held on April 9, 2026 is pending for utilization and is lying in Company's designated bank account(s), as on September 30th, 2026.

SANJAY GARG

Digitally signed by SANJAY GARG
Date: 2026.11.14 21:13:43 +05'30'